Last reviewed · How we verify
NCT03911453
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
EARLY_PHASE1 trial testing Rucaparib in Breast Cancer in 20 participants. Completed in 16 July 2021.
16 July 2021
Quick facts
| Lead sponsor | University of Arizona |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 19 April 2019 |
| Primary completion | 16 July 2021 |
| Estimated completion | 16 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rucaparib (RUCAPARIB) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
University of Arizona
Who can join
21 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm window of opportunity trial conducted in patients with early stage triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase (PARP) inhibitor will increase expression of programmed cell death-1 with ligand (PD-L1) in triple negative breast tumors.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103 -
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527 -
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
Porta FM, Sajjadi E, Venetis K, Frascarelli C, et al · · 2023 · cited 19× · PMID 37511789 · DOI 10.3390/jpm13071176 -
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y -
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W, Rajendran BK, Cui T, Sun J, et al · · 2025 · cited 3× · PMID 39450552 · DOI 10.3892/ijmm.2024.5447 -
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Masci D, Naro C, Puxeddu M, Urbani A, et al · · 2023
Verify or expand the search:
- PubMed search for NCT03911453
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rucaparib
Trials testing the same drug.
- NCT04676334 — CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib · Phase 3 · completed
- NCT03462212 — Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, · Phase 1, PHASE2 · unknown
- NCT04624178 — A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma · Phase 2 · active not recruiting
- NCT04826198 — Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Pa · Phase 1, PHASE2 · terminated
- NCT04539327 — Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Arizona trials
Trials by the same sponsor.
- NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
- NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
- NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
- NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
- NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03911453 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arizona
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03911453.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing